Literature DB >> 11607795

Resistance to antihypertensive medication as predictor of renal artery stenosis: comparison of two drug regimens.

B C van Jaarsveld1, P Krijnen, F H Derkx, J Deinum, A J Woittiez, C T Postma, M A Schalekamp.   

Abstract

BACKGROUND: Renal artery stenosis is among the most common curable causes of hypertension. The definitive diagnosis is made by renal angiography, an invasive and costly procedure. The prevalence of renal artery stenosis is less than 1% in non-selected hypertensive patients but is higher when hypertension is resistant to drugs.
OBJECTIVE: To study the usefulness of standardised two-drug regimens for identifying drug-resistant hypertension as a predictor of renal artery stenosis. DESIGN AND
SETTING: Prospective cohort study carried out in 26 hospitals in The Netherlands. PATIENTS: Patients had been referred for analysis of possible secondary hypertension or because hypertension was difficult to treat. Patients < or =40 years of age were assigned to either amlodipine 10 mg or enalapril 20 mg, and patients >40 years to either amlodipine 10 mg combined with atenolol 50 mg or to enalapril 20 mg combined with hydrochlorothiazide 25 mg. Renal angiography was performed: (1) if hypertension was drug-resistant, ie if diastolic pressure remained > or =95 mm Hg at three visits 1-3 weeks apart or an extra drug was required, and/or (2) if serum creatinine rose by > or =20 micromol/L (> or =0.23 mg/dL) during ACE inhibitor treatment.
RESULTS: Of the 1106 patients with complete follow-up, 1022 had been assigned to either the amlodipine- or enalapril-based regimens, 772 by randomisation. Drug-resistant hypertension, as defined above, was identified in 41% of the patients, and 20% of these had renal artery stenosis. Renal function impairment was observed in 8% of the patients on ACE inhibitor, and this was associated with a 46% prevalence of renal artery stenosis. In the randomised patients, the prevalence of renal artery stenosis did not differ between the amlodipine- and enalapril-based regimens.
CONCLUSIONS: In the diagnostic work-up for renovascular hypertension the use of standardised medication regimens of maximally two drugs, to identify patients with drug-resistant hypertension, is a rational first step to increase the a priori chance of renal artery stenosis. Amlodipine- or enalapril-based regimens are equally effective for this purpose.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11607795     DOI: 10.1038/sj.jhh.1001258

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  8 in total

Review 1.  Atherosclerotic renovascular disease.

Authors:  Sheldon W Tobe; Ellen Burgess; Marcel Lebel
Journal:  Can J Cardiol       Date:  2006-05-15       Impact factor: 5.223

Review 2.  Atherosclerotic-nephropathy: an updated narrative review.

Authors:  Mariadelina Simeoni; Silvio Borrelli; Carlo Garofalo; Giorgio Fuiano; Ciro Esposito; Alessandro Comi; Michele Provenzano
Journal:  J Nephrol       Date:  2020-04-08       Impact factor: 3.902

Review 3.  Review of resistant hypertension.

Authors:  C Venkata S Ram
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

Review 4.  Resistant hypertension.

Authors:  Sheldon W Tobe; Richard Lewanczuk
Journal:  Can J Cardiol       Date:  2009-05       Impact factor: 5.223

5.  Misleading results of randomized trials: the example of renal artery stenting.

Authors:  Samuel J Mann; Thomas A Sos
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-01       Impact factor: 3.738

Review 6.  Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis.

Authors:  Jeanie Park; Vito Campese
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

Review 7.  Atherosclerotic renovascular disease - epidemiology, treatment and current challenges.

Authors:  Diana Vassallo; Philip A Kalra
Journal:  Postepy Kardiol Interwencyjnej       Date:  2017-09-25       Impact factor: 1.426

8.  Renal Effects of Fetal Reprogramming With Pentaerythritol Tetranitrate in Spontaneously Hypertensive Rats.

Authors:  Andy W C Man; Min Chen; Zhixiong Wu; Gisela Reifenberg; Andreas Daiber; Thomas Münzel; Ning Xia; Huige Li
Journal:  Front Pharmacol       Date:  2020-04-29       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.